The UK’s automotive sector received a powerful shot in the arm this September, with a government-funded grant scheme acting as a potent medicine to revive a market that had been suffering from a “sluggish summer.” The record-breaking electric vehicle sales were a direct symptom of this successful intervention, breathing new life into the industry.
Before the grant was reintroduced in July, the market’s pulse was weak. Carmakers were struggling to meet their ZEV mandate targets, and consumer demand was being suppressed by economic anxiety. The industry was in clear need of a stimulant to get its heart rate back up.
The treatment administered was a subsidy of up to £3,750, and the patient responded immediately. The injection of affordability sparked a surge of activity, with pure EV sales jumping by nearly a third and plug-in hybrids by 56%. This boost was so strong that it lifted the entire market by 14%, showing its effect on the whole system.
This “shot in the arm” has helped the industry in two ways. Firstly, it has improved its immediate health by boosting sales volumes and revenues. Secondly, it is helping the sector meet its long-term health goals by accelerating the transition to the zero-emission products required by the ZEV mandate.
However, like any medical treatment, questions about long-term dependency arise. The industry has clearly benefited from this intervention, but its future health will depend on its ability to thrive once the effects of this potent, but temporary, medicine wear off.